BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2018 Earnings Results

Biocryst Pharmaceuticals Misses on EPS — Stock Down 9.5%

Biocryst Pharmaceuticals reported a larger-than-expected loss per share, which contributed to a significant drop in stock price by 9.5%. The lack of revenue data and guidance updates may have raised concerns among investors about the company's financial health and future prospects. The defensive tone from management suggests they are aware of the challenges ahead but are focused on long-term strategies.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.26	N/A	-42.09%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concerns about the current financial performance. They emphasized a commitment to strategic initiatives for future growth.

Management did not provide specific insights into revenue expectations.

The company is focusing on long-term growth despite current challenges.

Biocryst Pharmaceuticals Misses on EPS — Stock Down 9.5%

Key numbers

Management commentary

BioCryst Pharmaceuticals, Inc.

More earnings this week

Biocryst Pharmaceuticals Misses on EPS — Stock Down 9.5%

Key numbers

Management commentary